CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
ACOSOG-Z9031 ACSOG A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients with Retroperitoneal Sarcomas (RPS) Adult CIRB - Late Phase Emphasis
ADVL0221 COG A Phase II Study of Trabectedin (ET-743; Yondelis) in Children with Recurrent Rhabdomyosarcoma; Ewing Sarcoma; or Nonrhabdomyosarcomatous Soft Tissue Sarcomas Pediatric CIRB
ADVL0524 COG Phase II Trial of Ixabepilone (BMS-247550); an Epothilone B Analog; in Children and Young Adults with Refractory Solid Tumors Pediatric CIRB
ADVL0525 COG A Phase II Study of Pemetrexed in Children with Recurrent Malignancies Pediatric CIRB
ADVL06B1 COG A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer: A Group-Wide Non-Therapeutic Study Pediatric CIRB
ADVL0821 COG A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody; IND# 100947; NSC# 742460) in Children with Relapsed/Refractory Solid Tumors: A COG Groupwide Phase II Study Pediatric CIRB
ADVL0921 COG A Phase II Study of MLN8237 (IND# 102984); a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias Pediatric CIRB
ADVL1121 COG A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma; Wilms Tumor; Hepatocellular Carcinoma; and Papillary Thyroid Carcinoma Pediatric CIRB
ADVL1221 COG A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors Pediatric CIRB
ADVL1314 COG A Phase 1 Study of Eribulin Mesylate (E7389; IND #116;292); A Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS); Including Lymphomas: A Participation Limited to the COG Phase 1 Consortium Pediatric CIRB